ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zynex, Inc. (NASDAQ:ZYXI) on behalf of long-term stockholders following a class action complaint that was filed against Zynex on July 9, 2025 with a Class Period from March 13, 2023, to the present. Our investigation concerns whether the board of directors of Zynex have breached their fiduciary duties to the company.
The complaint alleges that the Individual Defendants began artificially inflating Zynex’s stock price by issuing or allowing false and misleading statements about the Company’s financial performance, operational practices, and compliance with insurance reimbursement policies. These statements concealed a systemic “oversupplying scheme” whereby Zynex shipped excessive quantities of supplies, such as electrode pads and batteries, to patients, billing insurers for thousands of dollars more than necessary. Zynex’s undisclosed practices drew scrutiny from insurers, including Tricare (the federal health insurer for the military), which represented 20–25% of its annual revenue.
The full extent of Zynex’s misconduct was finally revealed on March 11, 2025, when the Company issued a press release announcing fourth-quarter and full-year 2024 results. The release disclosed a significant revenue “shortfall” due to “slower than normal payments from certain payers” and revealed, “Tricare has temporarily suspended payments as they review prior claims.” The March 11, 2025, press release admitted that Tricare, representing 20% to 25% of Zynex’s annual revenue, was scrutinizing prior claims, threatening the Company’s financial stability.
The next day, on March 12, 2025, Zynex’s stock price plummeted $3.59 per share, or 51.3%, closing at $3.41 per share. This catastrophic decline wiped out significant shareholder value, reflecting the market’s reaction to Zynex’s exposure to regulatory and financial risks concealed by the Individual Defendants.
If you are a long-term stockholder of Zynex, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
